Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer.
Overview
Iovance Biotherapeutics is a growing biotechnology corporation with challenging and exciting opportunities for both junior and experienced professionals who are highly motivated and collaborative, with a passion to improve the lives of cancer patients around the globe.
Eligibility: Enrollment in a graduate degree program at a US institution. Candidate shall not be graduating sooner than September 2026.
Expected Start and Duration: